Guggenheim Begins Coverage on Tyra Biosciences (NASDAQ:TYRA)

Guggenheim initiated coverage on shares of Tyra Biosciences (NASDAQ:TYRA – Get Free Report) in a report released on Friday, MarketBeat reports. The firm set a “buy” rating and a $55.00 price target on the stock. Guggenheim‘s target price would indicate a potential upside of 173.36% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. William Blair raised Tyra Biosciences to a “strong-buy” rating in a research note on Wednesday, September 23rd. HC Wainwright dropped their target price on Tyra Biosciences from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Piper Sandler restated an “overweight” rating and set a $56.00 price target on shares of Tyra Biosciences in a report on Tuesday, September 8th. Finally, Oppenheimer restated an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a report on Tuesday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $47.50.

Check Out Our Latest Stock Analysis on TYRA

Tyra Biosciences Trading Up 2.0%

Shares of TYRA stock opened at $20.12 on Friday. Tyra Biosciences has a 1-year low of $18.25 and a 1-year high of $40.65. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -7.62 and a beta of 0.65. The stock’s fifty day simple moving average is $21.27 and its 200-day simple moving average is $29.09.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, sell-side analysts predict that Tyra Biosciences will post -2.78 EPS for the current year.

Institutional Trading of Tyra Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its stake in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after purchasing an additional 955,147 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of Tyra Biosciences during the 2nd quarter worth about $139,161,000. BlackRock Inc. purchased a new stake in shares of Tyra Biosciences during the 2nd quarter worth about $96,841,000. 5AM Venture Management LLC purchased a new stake in shares of Tyra Biosciences during the 2nd quarter worth about $32,875,778. Finally, Bank of America Corp DE acquired a new stake in shares of Tyra Biosciences during the 2nd quarter valued at about $11,170,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.

Further Reading

Analyst Recommendations for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.